Arsanis Inc (ASNS) Receives Consensus Rating of “Hold” from Analysts

Arsanis Inc (NASDAQ:ASNS) has earned a consensus rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $14.25.

Separately, ValuEngine lowered shares of Arsanis from a “buy” rating to a “hold” rating in a research note on Friday, January 4th.

Arsanis stock remained flat at $$3.11 during midday trading on Monday. 607,244 shares of the company traded hands, compared to its average volume of 62,844. Arsanis has a 52-week low of $1.15 and a 52-week high of $28.69. The firm has a market capitalization of $45.53 million, a PE ratio of -0.19 and a beta of 1.80. The company has a current ratio of 6.50, a quick ratio of 5.08 and a debt-to-equity ratio of 0.37.

A number of hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in Arsanis by 46.9% during the fourth quarter. Geode Capital Management LLC now owns 66,139 shares of the company’s stock worth $153,000 after buying an additional 21,111 shares during the period. Squarepoint Ops LLC boosted its stake in Arsanis by 117.9% during the fourth quarter. Squarepoint Ops LLC now owns 34,741 shares of the company’s stock worth $81,000 after buying an additional 18,796 shares during the period. Bank of New York Mellon Corp boosted its stake in Arsanis by 65.3% during the fourth quarter. Bank of New York Mellon Corp now owns 25,452 shares of the company’s stock worth $59,000 after buying an additional 10,056 shares during the period. BlackRock Inc. boosted its stake in Arsanis by 12.2% during the fourth quarter. BlackRock Inc. now owns 254,180 shares of the company’s stock worth $589,000 after buying an additional 27,542 shares during the period. Finally, Virtu Financial LLC boosted its stake in Arsanis by 54.6% during the fourth quarter. Virtu Financial LLC now owns 35,322 shares of the company’s stock worth $82,000 after buying an additional 12,469 shares during the period. 77.39% of the stock is owned by institutional investors.

Arsanis Company Profile

Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.

Recommended Story: Trading Strategy Methods and Types

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.